Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter financial results for the period ended September 30, 2026 announced.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter financial results for the period ended September 30, 2026 announced
- Exhibit 99.1 contains the company’s detailed results and management commentary
Item EX-99.1 · Exhibit EX-99.1
- Q3 net product revenue $21.0M, up from $15.8M, supporting commercial traction for ZYNLONTA
- Cash $189.2M at September 30, with expected runway into 2029 after financial restructuring
- $86.6M PIPE issued approximately 12.9M shares and 48M warrants at CHF 0.08, creating dilution risk
- Debt amendments reduced senior-loan principal by $68.5M to $50M and removed scheduled amortization and minimum liquidity covenant
- Q3 GAAP net loss $25.3M, or $0.16 per share, versus $41.0M, or $0.30, as operating expenses fell 24%
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.